Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Stock
Stocks
600196
CNE000000X38
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Shanghai S.E.
13/11/2026
|
5-day change | 1st Jan Change | ||
| 22.53 CNY | -1.23% |
|
-4.45% | -14.95% |
| 11-12 | Fosun Pharma Unit Begins Trial of Non-Hodgkin Lymphoma Drug in China | MT |
| 11-05 | Fosun Pharma Subsidiary Waives Right to Receive Transferred Shares in Biologics-Focused Equity Fund | MT |
| Market Cap | 55.33B 8.29B 7.51B 6.95B 6.27B 11.81B 782B 12.23B 83.45B 33.09B 417B 31.1B 30.44B 1,325B | P/E 2026 * |
16.5x | P/E 2027 * | 14.1x |
|---|---|---|---|---|---|
| Enterprise Value | 68.14B 10.21B 9.25B 8.56B 7.72B 14.55B 962B 15.06B 103B 40.75B 514B 38.31B 37.49B 1,632B | EV / Sales 2026 * |
1.63x | EV / Sales 2027 * | 1.73x |
| Free-Float |
62.59% | Yield 2026 * |
1.89% | Yield 2027 * | 2.17% |
| 1 day | -1.23% | ||
| 1 week | -4.45% | ||
| Current month | -0.57% | ||
| 1 month | -4.17% | ||
| 3 months | -7.78% | ||
| 6 months | -9.77% | ||
| Current year | -14.95% |
| 1 week | 22.5 |  | 23.73 |
| 1 month | 22.1 | | 23.79 |
| Current year | 20.85 | | 28.71 |
| 1 year | 20.85 | | 29.12 |
| 3 years | 20.38 | | 33.1 |
| 5 years | 20.38 | | 58.95 |
| 10 years | 20.38 | | 91.69 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yi Liu
CEO | Chief Executive Officer | 50 | 24/06/2025 |
Zhi Huang
DFI | Director of Finance/CFO | - | 02/04/2026 |
Jing Li
PSD | President | 53 | 01/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Qi Yu Chen
CHM | Chairman | 54 | 01/04/1994 |
Yi Liu
BRD | Director/Board Member | 50 | 02/12/2025 |
Dong Hui Pan
BRD | Director/Board Member | 56 | 30/06/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/30/25 A | Sell | Chief Executive Officer | 87,448 | 0.0041% | ||
| 5/30/25 A | Sell | Executive/Senior Manager | 31,790 | 0.0015% | ||
| 5/30/25 A | Sell | Chairman | 63,614 | 0.0030% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.23% | -4.45% | -21.99% | -20.11% | 8.29B | |
| +1.26% | +6.61% | +41.12% | +135.59% | 1,286B | |
| +0.79% | +3.45% | +46.35% | +93.56% | 688B | |
| +0.20% | +1.28% | +27.01% | +112.80% | 521B | |
| -0.44% | +3.69% | +39.60% | +69.51% | 386B | |
| +0.55% | +0.70% | +59.00% | +44.20% | 364B | |
| -0.12% | +0.74% | +26.78% | +58.43% | 302B | |
| +0.37% | +0.37% | +3.62% | +36.44% | 287B | |
| -0.30% | +1.14% | +38.59% | +74.61% | 252B | |
| +0.08% | +0.71% | +34.25% | +124.32% | 208B | |
| Average | +0.12% | +1.62% | +29.43% | +72.93% | 430B | |
| Weighted average by Cap. | +0.53% | +3.24% | +37.52% | +96.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 41.71B 6.25B 5.66B 5.24B 4.73B 8.9B 589B 9.22B 62.91B 24.95B 315B 23.45B 22.95B 999B | 43.42B 6.51B 5.89B 5.45B 4.92B 9.27B 613B 9.6B 65.5B 25.97B 328B 24.41B 23.89B 1,040B |
| Net income | 3.53B 529M 479M 443M 400M 754M 49.87B 780M 5.33B 2.11B 26.64B 1.98B 1.94B 84.56B | 4.2B 629M 570M 528M 476M 897M 59.35B 929M 6.34B 2.51B 31.7B 2.36B 2.31B 101B |
| Net Debt | 12.81B 1.92B 1.74B 1.61B 1.45B 2.74B 181B 2.83B 19.32B 7.66B 96.66B 7.2B 7.05B 307B | 19.74B 2.96B 2.68B 2.48B 2.24B 4.22B 279B 4.36B 29.78B 11.81B 149B 11.1B 10.86B 473B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/11/26 | CN¥22.53 | -1.23% | 11,222,633 |
| 12/11/26 | CN¥22.81 | -0.48% | 12,642,215 |
| 11/11/26 | CN¥22.92 | -2.05% | 14,656,600 |
| 10/11/26 | CN¥23.40 | +1.25% | 14,807,507 |
| 09/11/26 | CN¥23.11 | -1.99% | 15,274,465 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- 600196 Stock
Select your edition
All financial news and data tailored to specific country editions
